SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Carlin BI,Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000; 88( 12 suppl): 29892994.
  • 2
    Janjan N. Bone metastases: approaches to management. Semin Oncol. 2001; 28(4 suppl 11 ): 2834.
  • 3
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80( 8 suppl): 15881594.
  • 4
    Saad F,Gleason DM,Murray R, et al, for the Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 14581468.
  • 5
    Saad F,Gleason DM,Murray R, et al, for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879882.
  • 6
    Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
  • 7
    Novartis International AG. Zometa (zoledronic acid). EU summary of product characteristics. Basel, Switzerland: Novartis International AG; 2005.
  • 8
    Chang JT,Green L,Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003; 349: 16761679.
  • 9
    Mazj S,Lichtman SM. Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol. 2004; 22( suppl): 735. Abstract 8039.
  • 10
    Markowitz GS,Fine PL,Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64: 281289.
  • 11
    Stein SH,Davidson R,Tweed A, et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer. J Clin Oncol. 2003; 21( suppl): 745. Abstract 2997.
  • 12
    Kloth DD,McDermott RS,Rogatko A, et al. Impact of zoledronic acid (Zol) on renal function in patients (pts) with cancer: is constant monitoring necessary? J Clin Oncol. 2003; 21( suppl): 755. Abstract 3036.
  • 13
    Johnson KB,Gable P,Kaime EM, et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. J Clin Oncol. 2003; 22: 738. Abstract 2968.
  • 14
    Cockcroft DW,Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 3141.
  • 15
    Thadhani R,Pascual M,Bonventre JV. Acute renal failure. N Engl J Med. 1996; 334: 14481460.
  • 16
    Andersen PK,Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982; 10: 11001120.
  • 17
    Small EJ,Smith MR,Seaman JJ,Petrone SKowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003; 21: 42774284.
  • 18
    Rosen LS,Gordon D,Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377387.